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Standard–titre  Schwarz  (SW)  and  Edmonston-Zagreb  (EZ)  measles  vaccines  (MV)  are  both  used  in  the  rou-
tine  immunisation  programme.  Within  a  trial of  different  strains  of  MV,  we  examined  antibody  responses
in  both  one-dose  and  two-dose  schedules  when  the  ﬁrst  dose  was  administered  at  9 months.
Setting and Methods:  The  trial  was  conducted  in  an  urban  area  in  Guinea-Bissau  where  we  have  had  a
health  and  demographic  surveillance  system  and  studied  strategies  to  prevent  measles  infection  since
1978.  In the  present  study,  children  were  randomised  to  SW  or EZ  as  the  ﬁrst  MV  and  furthermore
randomised  to  a second  dose  of  the  same  MV  or no vaccine  at 18 months  of  age.  We  obtained  blood
samples  from  996  children  at baseline;  post-vaccination  blood  samples  were  collected  at  18  and  24
months  of  age  to  assess  measles  antibody  levels  after  one  or  two  doses  of  MV.
Results: At  age  18  months  all had  responded  to  the  ﬁrst dose  and  only  1% (8/699)  of  the  children  had
non-protective  antibody  levels  irrespective  of  vaccine  type.  SW  was  associated  with  signiﬁcantly  higher
levels  of measles  antibodies  (geometric  mean  titre  (GMT)  =  2114  mIU/mL  (95%CI  1153–2412))  than  EZ
(GMT  =  807  mIU/mL  (722–908))  (p =  0.001).  Antibody  concentration  was  signiﬁcantly  higher  in  girls than
in  boys  after  EZ  but  not  after  SW.  Antibody  levels  were  higher  in the  rainy  than  the  dry  season.  There  was
no  clear  indication  that  a booster  dose  at 18  months  increased  the  antibody  level  at  24  months  of  age.
Conclusions: Maternal  antibody  levels  have  declined  signiﬁcantly  in  recent  years  and  99%  had  protective
levels  of  measles  antibody  following  primary  MV  at  9  months  of  age.  It  is  unlikely  that  measles  prevention
and  child  health  will  be  improved  by  increasing  the  age  of  MV  as  currently  recommended.
© 201 .. Background
The two measles vaccines (MV) most commonly used in
ow-income countries are standard-titre Schwarz (SW) and
dmonston-Zagreb (EZ) vaccine. After discontinuation of high-titre
V [1], two-dose MV  schedules were suggested to lower the age of
V [2]. From 1995 to 2002, all children in the Bandim Health Project
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(BHP) study area in Bissau were offered enrolment in an early two-
dose MV  trial from 6 months of age [3–6]. The two-dose schedule
increased coverage considerably and provided better protection
against measles among infants than one-dose at 9 months of age
schedule [4]. EZ and SW MV  were used for different cohorts within
the trial and EZ MV seemed to provide a better booster response
than SW MV  [5]. We  have therefore been interested in comparing
EZ and SW MV  in a randomised trial of two-dose schedules.
According to WHO  and UNICEF plans all children should be guar-
anteed a second opportunity for MV either through campaigns or
routine immunisation [7]. In Latin America, MV  campaigns have
been introduced to support routine immunizations and the admin-
Open access under CC BY-NC-ND licenseistration of the ﬁrst vaccine has been postponed to 12 months
because seroconversion is believed to be better after 12 months of
age [8]. It has been suggested to increase the age of vaccination in
other regions when measles comes under control [9]. An increase
 license.
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n age of primary MV could dramatically enlarge the number of
usceptible infants in crowded urban areas in Africa [10,11]. Many
bservational studies and a few randomised trials have indicated
hat MV has non-speciﬁc beneﬁcial effects by providing protection
gainst other infections than measles, in particular against lower
espiratory infection [3,6,12–15]. Increasing the age of administra-
ion would therefore limit the beneﬁcial non-speciﬁc effects of MV.
hus ﬁnding the best schedule and vaccine strain for use in a rou-
ine two-dose schedule might be the best approach for the African
egion. We  have therefore conducted studies of both early (4½ and 9
onths) and later (9 and 18 months of age) two-dose MV  strategies
11,14]. In the present paper we compare the antibody response
f standard-dose EZ and SW MV  when administered at 9 and 18
onths of age.
.  Methods
.1. Setting
The trial was conducted at the Bandim Health Project (BHP),
hich has a demographic surveillance system in several districts of
he capital of Guinea-Bissau between 2003 and 2007. The current
opulation is around 102,000. All houses are visited every month
o register new pregnancies and births. The BHP ﬁeld-workers visit
ll children every 3 months until the age of 3 years to collect
nformation on breastfeeding patterns, infections, hospitalisation,
accinations, and socio-economic characteristics.
.2. Study design
The  present serological study initiated in 2004 was part of a
andomised trial [11,14]. Children were enrolled at 4.5 months and
andomised to one of three groups: Group I received EZ MV  at 4.5
nd 9 months, Group II SW MV  at 9 months, and Group III EZ MV
t 9 months of age. At 9 months of age the children were invited
ack to one of the three health centres in the study area; Group I
eceived a second dose of EZ MV,  Group II received their ﬁrst dose
f SW MV,  and group III the ﬁrst dose of EZ. At 18 months children
rom groups II and III were invited back. If the mothers consented,
he children were randomised to receive a second dose of the same
train of MV  or no second dose of MV  (Supplementary Fig. 1). The
resent analysis deals only with groups II and III.
.3. Enrolment
Newborn infants were identiﬁed in the BHP register. To make
ure that all children had received three doses of diphtheria, tetanus
nd pertussis (DTP) vaccine four weeks before inclusion in the trial,
e contacted mothers of children aged 6, 10 and 14 weeks, and
eminded them to go to the local health centre to receive the oral
olio vaccine (OPV) and DTP vaccine. Children were enrolled at 4.5
onths of age. In the morning a ﬁeld-worker contacted the moth-
rs/guardians of eligible children, explained the study, ﬁlled in a
uestionnaire on background factors, and obtained verbal consent.
others were asked to bring their children to the health centre
n the afternoon. The trial physician provided attending moth-
rs/guardians with an oral and a written explanation of the study.
t each health centre visit the children were examined by the
hysician. Clinical examination and treatment was independent of
andomisations group. Children who were sick and needed admis-
ion to hospital could only participate when they had recovered..4.  Randomisation and intervention
The data manager, who was not involved in enrolment pro-
edures, prepared bags with 24 numbered envelopes indicating1 (2013) 5766– 5771 5767
the  randomisation group. These numbers could not be seen by
the physician informing and obtaining consent from the moth-
ers/guardians. Following consent the mothers/guardians were
asked to select one envelope. We  used block randomisation with
24 envelopes per bag.
2.5.  Measles vaccines
Standard-titre EZ MV  from the Serum Institute of India, Pune,
India, (batch 2360) and standard-titre SW MV (Rouvax) from
Aventis, France, (batch w5556-1, wx5491-2) were used. MV  was
administered subcutaneously with 23G needles in the upper part
of the back. No other vaccine was  given at the same time.
2.6.  Sample size
We  needed 400 children per group to detect a 10% difference in
the proportion of non-seroconverters.
2.7.  Blood sampling and antibody analysis
We collected blood samples at 9, 18 and 24 months in Group II
and III. The mothers were sampled at the ﬁrst contact. The 9 month
sample was  a pre-vaccination sample and should mainly reﬂect
maternal antibody levels. The sample at 18 months was collected
prior to a possible second dose of MV  and was  therefore used to
assess antibody levels after the ﬁrst dose of MV at 9 months of age.
The sample at 24 months of age was  intended to measure long-
term maintenance of antibody levels and to examine the possible
booster effect of a second dose of MV.
Samples were analysed by the measles haemagglutination inhi-
bition test (HAI) at the MRC  Laboratories in Gambia [16,17].
Sensitivity was 15.6 mIU/mL and with a starting 1:2 dilution, the
minimum detectable titre was  31.2 mIU/ml. The protective anti-
body level is 125 mIU/mL, a positive reading in the 1:8 dilution.
Children with 31–63 mIU/ml have low non-protective measles
antibody levels.
2.8.  Measles epidemic and antibody levels
The study area experienced a measles epidemic between May
2003 and May  2004. Since the antibody started in March 2004
some of the ﬁrst children enrolled in the serological study may
have had clinical measles or subclinical measles [11,18]. There was
no measles infection when the 18 and 24 months samples were
collected. The children with clinical measles have been excluded
from the analysis (see Supplementary Fig. 1). The level of measles
antibody after subclinical infection is difﬁcult to deﬁne. However,
we have assumed that most children who had protective measles
antibody levels at 9 months of age (see Supplementary Fig. 1)
were likely to have locally produced antibodies after subclinical
infection rather than (high) maternal measles antibody [18]. This
interpretation is supported by several lines of evidence, ﬁrst, the
mother of children who had “protective level at 9 months” did
not have higher antibody levels than mothers of children with
non-protective levels at 9 months; second, whereas girls had lower
level of maternal measles antibody levels at 4.5 months of age than
boys, they had higher levels than boys at 9 months of age, and only
subclinical infection seems to able to explain this inversion in the
antibody levels of girls and boys; and third, following vaccination
at 9 months of age, children with “protective level at 9 months”
continued to have a high level at 18 and 24 months of age which
was presumably due to boosting of acquired immunity by sub-
clinical infection (see below). Had the high level at 9 months been
due to maternal measles antibody, we should have seen a reduced
5768 C.  Martins et al. / Vaccine 31 (2013) 5766– 5771
Table 1
Background factors for the SW and EZ groups at enrolment.
SW EZ
Background factor
Number  441 (49%) 455 (51%)
Boys 51% (226) 51% (233)
Mean age at inclusion 4.96 months 4.99 months
District: % Bandim 45% (119) 42% (191)
Risk factors at enrolment
Not  breastfed at 4.5 months 3% (11) 3% (13)
Pigs in household 14% (62) 15% (66)
Mean number of persons/bed 3.1 2.9
Toilet inside 15% (64) 16% (71)
Functioning electricity 25% (105) 28% (119)
Morbidity and anthropometry
Hospitalization before 4.5 months 1.4% (6) 1.5% (7)
Mean weight 7.11 g 7.22 g
Mean  height 64.4 cm 64.5 cm
Mean  child arm-circumference 141 mm 142 mm
Mean  maternal arm-circumference 273 mm 271 mm
a
a
2
t
v
p
G
s
h
ﬁ
3
m
f
4
7
(
G
4
s
d
e
w
h
g
b
(
s
w
an
ti
bo
d
y 
ti
tr
es
 
at
 
9 
an
d
 
18
 
m
on
th
s 
be
fo
re
 
an
d
 
af
te
r 
th
e 
ﬁ
rs
t 
d
os
e 
of
 
Sc
h
w
ar
z 
(S
W
) 
or
 
Ed
m
on
st
on
-Z
ag
re
b 
(E
Z)
 
m
ea
sl
es
 
va
cc
in
e 
by
 
se
x 
an
d
 
se
as
on
.
G
M
T 
at
 
9 
m
on
th
s 
of
 
ag
e 
be
fo
re
M
V
 
at
 
9 
m
on
th
s 
of
 
ag
e
G
M
T  
at
 
18
 
m
on
th
s 
of
 
ag
e 
af
te
r 
ﬁ
rs
t 
d
os
e 
of
M
V
 
at
 
9 
m
on
th
s 
of
 
ag
e
G
M
T  
at
 
18
 
m
on
th
s 
of
 
ag
e 
af
te
r 
ﬁ
rs
t 
d
os
e 
of
M
V
 
at
 
9 
m
on
th
s 
of
 
ag
e
A
ll
 
bo
ys
 
gi
rl
s 
P*
 
A
ll
 
B
oy
s 
G
ir
ls
 
P*
 
R
ai
n
y 
D
ry
 
P*
 
N
 
40
7 
21
4 
19
3 
0.
53
 
35
5 
19
0 
16
5 
0.
37
 
22
2 
13
3 
0.
04
G
M
T(
95
%
 
c.
i.)
 
21
 
20
 
23
 
21
14
 
20
13
 
22
34
 
22
81
 
18
53
(1
9–
23
) 
(1
7–
22
) 
(1
9–
27
) 
(1
85
3–
24
12
) 
(1
68
2–
24
11
) 
(1
84
0–
27
13
) 
(1
85
3–
24
12
) 
(1
47
4–
23
12
)
Pr
op
or
ti
on
 
n
on
-p
ro
te
ct
ed
38
4/
40
7 
20
5/
21
4 
17
9/
19
3 
5/
35
5 
2/
19
0 
3/
16
5 
3/
22
2 
2/
13
3
 
N
 
41
5 
21
1 
20
4 
0.
32
 
34
4 
17
2 
17
2 
0.
02
 
21
0 
13
4 
0.
47
G
M
T(
95
%
 
c.
i.)
 
23
 
21
 
26
 
80
7 
70
2 
92
6 
83
4 
76
3
(2
0–
26
) 
(1
8–
24
) 
(2
1–
31
) 
(7
22
–9
08
) 
(6
07
–8
18
) 
(7
79
–1
09
4)
 
(7
27
–9
66
) 
(6
33
–9
20
)
Pr
op
or
ti
on
 
n
on
-p
ro
te
ct
ed
 
38
2/
41
5 
19
8/
21
1 
18
4/
20
4 
3/
34
4 
1/
17
2 
2/
17
2 
2/
21
0 
1/
13
4
0.
57
 
0.
60
 
0.
39
 
0.
00
 
0.
00
 
0.
00
 
0.
00
 
0.
00
st
 
of
 
an
y 
d
if
fe
re
n
ce
 
in
 
an
ti
bo
d
y 
le
ve
l a
cc
or
d
in
g 
to
 
ge
n
d
er
 
or
 
se
as
on
.BCG  scar 80% (354) 80% (364)
ntibody response due to vaccination in the presence of maternal
ntibody.
.9. Statistical analysis
The  statistical analysis was performed in STATA 10.0. Antibody
itre data were log-transformed and presented as geometric mean
alues (GMT) with 95% conﬁdence intervals (CI). We  compared the
roportion with non-protective antibody levels in groups II and III.
MTs were compared using non-parametric Kruskal–Wallis analy-
is. We  stratiﬁed analyses by sex. Since previous studies have found
igher antibody levels during the rainy season [16], we also strati-
ed by season.
.  Results
The number of samples and follow-up is depicted in Supple-
entary Fig. 1. There were no signiﬁcant differences in background
actors between SW and EZ groups (Table 1).
. Measles antibody levels of the mothers
Of the 818 samples from mothers of children in groups II and III,
 had insufﬁcient blood for analysis. Among the remaining 811, 4%
35/811) had non-protective antibody levels (<125 mIU/mL). The
MT  among mothers was 1052 mIU/mL (95% CI 953–1162).
.1.  Measles antibody levels at 9 months of age
A total of 896 children were tested at 9 months before MV.  Two
amples were excluded due to insufﬁcient amount of blood; 65 chil-
ren had already had measles infection; 5 children had received MV
lsewhere, and two received the wrong MV.  Hence, 822 children
ere included in the analyses (Table 2).
At 9 months, the GMT  was 22 mIU/mL (20–24); 7% (56/822)
ad “protective levels at 9 month”. As reported elsewhere [17],
irls were more likely to have protective levels (9% (34/397)) than
oys (5% (22/425)), the relative risk (RR) being 1.65 (0.98–2.78)
p = 0.054). Mothers of children who had a protective level had the
ame antibody level (GMT = 1055 mIU/mL) as mothers of children
ho had non-protective levels at 9 months (GMT = 1001 mIU/mL). Ta
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Table  3
Geometric mean measles antibody titres (GMT) at 18 months of age after the ﬁrst dose of Schwarz or Edmonston-Zagreb vaccine depending on pre-vaccination antibody
levels.
Antibody level at 9 months N Schwarz measles vaccine Edmonston-Zagreb measles vaccine
GMT  (95%CI) N GMT (95%CI) N
31–25
5–301
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31–63  mIU/ml 44 1257(52
≥125  mIU/ml 56 1866(91
.2. Vaccine-induced measles antibody levels at 18 months after
rst  dose of MV
Of  the 822 children who participated at 9 months of age, 407
hildren belonged to the SW group and 415 to the EZ group. At 18
onths in SW group, 9 samples were erroneously not collected, 19
hildren had moved, 6 had died, 14 were absent, 2 had other reasons
or not being bled, and 2 samples were insufﬁcient for analysis (Sup-
lementary Fig. 1). In the EZ group, 12 samples were erroneously
ot collected, 26 children had moved, 11 had died, 18 were absent,
nd 4 had other reasons (Supplementary Fig. 1). The remaining 355
amples in the SW group and 344 in the EZ group were included in
he analysis of antibody levels after vaccination.
The prevalence of unprotected children at 18 months after the
rst dose of MV  was the same in the SW group (1.4% (5/355))
nd in the EZ group (0.9% (3/344)). The SW children had signif-
cantly higher levels (GMT = 2114 mIU/mL) than children in the
Z group (GMT = 807 mIU/mL)(p = 0.001) (Table 2). Girls in the EZ
roup (GMT = 926 mIU/mL) had signiﬁcantly higher levels than EZ
oys (GMT = 702 mIU/mL)(p = 0.022) but there was  no signiﬁcant
ifference in the SW group (Table 2). In the SW group, antibody
evels were higher in the rainy season (GMT = 2281 mIU/mL) than
n the dry season (GMT = 1853 mIU/mL)(p = 0.040) whereas there
as no seasonal difference in the EZ group (Table 2).
The  GMT  at 18 months of age in the SW group was  not statis-
ically signiﬁcant in children who had had undetectable antibody
evels at 9 months (GMT = 2203 mIU/mL (1931–2514)) and in chil-
ren with low non-protective antibody levels (GMT = 1257 mIU/mL
525–3010)) (p = 0.74) (Table 3). The same was seen for the EZ
roup. However, there were few children with low non-protective
ntibody levels and it was therefore difﬁcult to assess whether such
ow levels affects the subsequent response to MV.  Children with
rotective antibody levels at 9 months of age who presumably had
ubclinical infection before 9 months of age (Table 3) had higher
ntibody levels at 18 months of age. Hence, presumably their level
t 9 months of age was due to locally produce antibody after sub-
linical infection since high maternal antibody levels would have
educed the antibody response to MV.
.3. A booster dose of MV:  antibody concentrations at 24 months
f  age
At 24 months, the proportion of children having non-protective
evels was again very small in both groups and in both the one-
ose and two-dose arms of these groups (Table 4). At 24 months
irls still had signiﬁcantly higher antibody level than the boys in
he EZ group (data not shown). In both groups, the antibody level
ncreased between 18 and 24 months regardless of whether or
ot they received a booster dose at 18 months (Table 4). Though
he level increased the relative difference in level between SW
nd EZ remained the same at 24 months of age. There was no
ifference in the antibody level at 24 months for those who  had
eceived a booster at 18 months and those who had not received
 booster (Table 4). We  tested how many had a 4-fold increase in
itre between 18 and 24 months of age (Table 4). The proportion
ith a signiﬁcant increase was essentially the same in the EZ and14) 313 779(693–877) 301
0) 21  757(418–1376) 15
7) 21 1214(697–2114) 28
SW  arms of the study and did not depend on whether the children
had a booster dose at 18 months (Table 4). However, there was
a marked tendency that children with relative low levels of anti-
bodies (0–500 mIU/mL) were more likely to have a 4-fold increase
(RR = 2.53 (1.89–3.39)). Among children with low levels of antibod-
ies a 4-fold increase may  have been more likely among children
who had a booster vaccination at 18 months, but this tendency
was not statistically signiﬁcant.
5.  Discussion
5.1. Main observations
There  were several important observations. First, maternal anti-
body levels had declined further; the GMT  for the mothers was
1052 mIU/mL in 2004 whereas it had been 2253 mIU/ml  during
our previous study of early MV  in the mid-1990s [5]. In the late
1990s, 67% of the mother were immunised had not had nat-
ural infection [19]. The proportion of immunised would have
increased when the present study started in 2004 and more than
93% of the children did not have protective antibody levels at 9
months. The present study took place shortly after a measles epi-
demic. The 7% of the children who  had protective antibody levels
at 9 months are likely to have had sub-clinical measles infec-
tion rather than particularly high maternal antibody levels [18];
when the children with protective levels at 9 months were vac-
cinated they continued to have high measles antibody whereas
high maternal antibody levels would have prevented or reduced
the response to MV.  Hence, nearly all children had non-protective
levels at 9 months of age and most infants of well-vaccinated moth-
ers become susceptible to clinical measles well before 9 months
of age.
Second, essentially all children had protective antibody levels
after one dose of EZ or SW at 9 months of age. One  percent of
the children tested had non-protective levels at either 18 or 24
months of age. However, different children had low levels at 18
and 24 months of age so ultimately everyone had been protected by
the vaccine. It seems unlikely that much could be gained in effec-
tive immunisation coverage by increasing the age of vaccination
[9].
Third, surprisingly there was  little indication of an overall boost-
ing effect of either EZ or SW given at 18 months of age. There may
have been a slight tendency that children with low levels at 18
months were more likely to have a 4-fold increase in titre at 24
months if they had received a second dose. It is worth noting that
the general antibody level increased from 18 to 24 months of age.
We have no explanation for this trend; 18-month and 24-month
samples may  have been measured at different assay days but the
antibody assay and internal controls used over the study was  the
same. With this general increase the effect of booster might not
have been seen. It has previously been described that measles anti-
body levels following MV  before 9 months of age and at 9 months
of age continued to increase at the second post-vaccination sam-
ple [20]. Something similar might have occurred in the second year
of life though a post-vaccination increase in antibody level has not
previously been examined this late. As discussed above it is unlikely
5770 C.  Martins et al. / Vaccine 31 (2013) 5766– 5771
Table 4
Geometric mean titres (GMT) at 24 months of age after 1 or 2 doses of Schwarz (SW) or Edmonston-Zagreb (EZ) measles vaccine according to antibody levels at 18 months
of age.
(A) Schwarz measles vaccine (Group II)
Received booster SW at 18 months No booster at 18
months
GMT  at 18 months of age
after  ﬁrst dose of MV
Non-protective
levels
GMT  (95% CI) 4-fold or larger
increase 18–24
months
Non-protective  levels GMT  (95% CI) 4-fold or larger
increase 18–24
months
<125 mIU/ml 0% (0/2) 356 100% (2/2) 100% (1/1) NA NA
125–500 mIU/ml 0% (0/24) 812 (566–1164) 54% (13/24) 5% (1/20) 634 (406–993) 35% (7/20)
≥1000 mIU/ml 0% (0/136) 4924 (4141–5897) 21% (29/136) 0% (0/132) 4055 (3363–4856) 22% (29/132)
Total 0% (0/162) 3681 (3031–4444) 27% (44/162) 1% (2/153) 3074 (2500–3782) 24% (36/153)
(B) EZ measles vaccine (Group III)
Received booster EZ at 18 months No booster at 18 months
GMT  at 18
months of age
after  ﬁrst dose
of  MV
Non-protective levels GMT  (95% CI) 4-fold or larger
increase  18–24
months
Non-protective levels GMT  (95% CI) 4-fold or larger
increase 18–24
months
<125 mIU/ml 0% (0/2) 500 (332–698) 100% (2/2) 0% (0/1) 2000 100% (1/1)
125–500  mIU/ml 4% (3/77) 742 (594–920) 42% (32/77) 1% (1/72) 812 (632–1042) 38% (27/72)
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t≥1000  mIU/ml 0% (0/86) 2042 (1659–2497) 13%
Total  2% (3/165) 1257 (1064–1485) 27% (
otes: NA = not applicable.
hat exposure to measles cases has played a major role. Assay vari-
bility could also have played a role but the assay was  standardised
nd across batches there was little variability so this seems unlikely.
Fourth, there were differences in antibody levels by gender.
 previous study from Guinea-Bissau showed that there was  no
ifference in GMT  between boys and girls before vaccination at
 months of age but after vaccination with the EZ strain vaccine
t 9 months of age, girls had signiﬁcantly higher antibody levels
han boys and borderline signiﬁcantly in the SW vaccine [5]. In the
resent study girls had a greater response at both 18 and 24 months
f age which was signiﬁcant in the EZ group. We  have also previ-
usly observed higher response of girls than boys to SW MV  [21],
his trend was however changed when the children received vita-
in  A with MV.  There is no real explanation of these trends except
hat females may  have a stronger Th2 proﬁle and higher antibody
esponses than males [22].
.2. Strength and weaknesses
Since  EZ and SW are the two main strains used in low-income
ountries it is important to understand their impact on antibody
esponses and long-term maintenance of antibody levels and their
mpact on child survival. The present study was  started for this
urpose.
Unexpectedly an epidemic occurred between May  2003 and
ay 2004 just when the present trial was started. The 9 month
amples were collected between March and December 2004 and
any of the children had already contracted measles before they
ere sampled and some may  have had subclinical measles. The
pidemic ended before children had received 9 month vaccination.
nly two children had measles after the 9 months vaccination and
t is therefore unlikely that the epidemic had any impact on how
e measured the antibody response to MV  at 9 months. The sample
ize was reduced since we excluded children who had already had
easles and some samples were difﬁcult to interpret as to whether
hey might represent subclinical measles or high maternal antibody
evels. Still we had more than 300 children in the main groups.We  have previously documented in both Guinea-Bissau and
enegal that the antibody level of children born to women immu-
ised in childhood was only half the antibody level of children born
o women who had had natural measles infection [19,23]. So the6) 0% (0/77) 2016 (1593–2554) 17% (13/77)
5) 1% (1/150) 1310 (1087–1569) 27% (41/150)
decreased  level of maternal measles antibody between our previ-
ous study in the mid- 1990s and the present study is likely related
to an increased proportion of the mothers having been immunised
rather than naturally infected with measles.
The present study was conducted in an area in which measles
vaccination studies have been conducted since the mid-1980s
and the coverage of MV  may  therefore be somewhat higher and
the maternal antibody levels somewhat lower than in other low-
income countries. On the other hand, it is an urban area with a very
mobile population and the population has increased more than
ﬁve-fold over the last 20 years so few of the current women of
fertile age will have beneﬁtted from our earlier vaccination cam-
paigns. If anything the MV  coverage in Guinea-Bissau has probably
been slightly lower than in other African countries over the last 25
years. Hence, it is unlikely that the maternal measles antibody level
found in Guinea-Bissau is particularly low.
5.3. Interpretations and implications
As maternal antibody was  low essentially everybody serocon-
verted when vaccinated with EZ or SW at 9 months. In absence of
maternal antibodies SW MV  induces higher antibody levels than EZ
MV  [5]. This difference in antibody levels persisted at 24 months
of age. We  have previously shown that EZ at 4–6 months of age
provided protection as good as that given by SW at 9 months [11].
If clinical protection against measles was  only determined by anti-
bodies, the SW MV  would seem a better candidate for a single dose
strategy. However, it has not been examined whether there is any
difference in protection when EZ and SW are administered at 9
months of age, or in other words whether the difference in anti-
body levels after the initial vaccination is related to a difference
in protection against measles infection. We  will follow these chil-
dren to examine whether there is any difference in protection or in
decline of antibody levels. However, with current data there is no
reason to think that there is any signiﬁcant difference between EZ
and SW in protection.
Current  MV  policy is based on the idea that at better to wait
with MV  until maternal antibodies have waned completely and it
is therefore recommended to raise the age of primary MV  to 12
months once MV  is under control; for example, the age of vacci-
nation was  raised to 12 months in Latin America in 1996 when
cine 3
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easles had been eliminated. However, all children vaccinated at
 months seroconverted to measles and it is unlikely that increas-
ng the age of MV  could substantially improve seroconversion and
easles protection [9]. Increasing the age of primary MV  would
ncrease the pool of susceptible children and increase the risk of epi-
emics and this is likely to be aggravated because later vaccination
s likely to be associated with a lower coverage. Furthermore, an
ncreasing number of observational studies and randomised trials
ave shown that MV  has non-speciﬁc beneﬁcial effects providing
ome protection against other infections than measles [3,7,12–15].
ncreasing the age of primary MV  would reduce the period in which
hildren beneﬁtted from the non-speciﬁc effects and might con-
ribute to increased childhood mortality. If we  want to optimise
he overall impact of MV  on child health, rather than just speciﬁc
easles protection, there are good reasons to consider a lower age
f vaccination for the ﬁrst measles vaccine. Randomised trials in
uinea-Bissau and Sudan have found marked beneﬁcial effects on
hild survival of two-dose MV  schedules with the ﬁrst dose pro-
ided around 4–5 months of age [15].
WHO and GAVI now recommend a second dose of measles con-
aining vaccine in the second year of life; for example, several West
frican countries have recently received GAVI support to introduce
he second dose at 15–18 months of age. Our present study suggests
hat a second MV  around 18 months of age may  contribute little to
eroconversion and antibody levels. However, the studies of two-
ose MV  schedules have suggested that the second dose also has a
eneﬁcial effect on child survival. The appropriate response must
e to examine different schedules with different timing of the ﬁrst
nd the second dose for their overall effect on child health rather
han just continue with the 9-month MV  policy which was  deﬁned
early 40 years ago when maternal measles antibody levels were
ery different [15].
.  Conclusions
Both SW and EZ MV  administered at 9 months of age induced
rotective measles antibody levels in 99% of the children. SW
nduced higher antibodies levels than EZ MV  but it is not known
hether this translates into a better protection against measles
nfection. It seems unlikely that increasing the age of MV  could
mprove protection against measles.
Trial registration: Clinical trials NCT00168558
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